Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

The notorious adult entertainer admits that extreme sex stunts are her thing, but at what point is she pushing herself too ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...